Courtney E. Bakan

1.9k total citations · 1 hit paper
16 papers, 1.6k citations indexed

About

Courtney E. Bakan is a scholar working on Hematology, Immunology and Molecular Biology. According to data from OpenAlex, Courtney E. Bakan has authored 16 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 11 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Courtney E. Bakan's work include Multiple Myeloma Research and Treatments (12 papers), Immune Cell Function and Interaction (10 papers) and Glycosylation and Glycoproteins Research (3 papers). Courtney E. Bakan is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Immune Cell Function and Interaction (10 papers) and Glycosylation and Glycoproteins Research (3 papers). Courtney E. Bakan collaborates with scholars based in United States, France and Denmark. Courtney E. Bakan's co-authors include Don M. Benson, Craig C. Hofmeister, Yvonne A. Efebera, Michael A. Caligiuri, Jianhua Yu, Jianying Zhang, Steven M. Devine, Megan Smith, John C. Byrd and Pierluigi Porcu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Courtney E. Bakan

16 papers receiving 1.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

2010 660 citations Don M. Benson, Courtney E. Bakan et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Courtney E. Bakan United States	10	1.0k	937	567	414	116	16	1.6k
Mingzhong Zheng United States	11	232 0.2×	393 0.4×	340 0.6×	596 1.4×	43 0.4×	16	1.0k
Puru Nanjappa United States	10	263 0.3×	473 0.5×	433 0.8×	512 1.2×	61 0.5×	23	1.0k
Ella Willenbacher Austria	12	222 0.2×	233 0.2×	301 0.5×	273 0.7×	61 0.5×	32	735
Patricia Gomez‐Bougie France	22	201 0.2×	395 0.4×	463 0.8×	1.0k 2.5×	43 0.4×	38	1.3k
Iris Breitkreutz United States	14	204 0.2×	697 0.7×	1.0k 1.8×	879 2.1×	113 1.0×	34	1.5k
D Chauhan India	8	134 0.1×	563 0.6×	675 1.2×	1.1k 2.8×	16 0.1×	29	1.6k
Jos de Graaf Germany	11	809 0.8×	666 0.7×	98 0.2×	545 1.3×	132 1.1×	14	1.4k
Hannah J. Lomax-Browne United Kingdom	11	326 0.3×	106 0.1×	130 0.2×	312 0.8×	77 0.7×	15	752
Paweł Robak Poland	19	186 0.2×	372 0.4×	410 0.7×	539 1.3×	68 0.6×	86	1.1k
Juraj Bodo United States	17	240 0.2×	354 0.4×	252 0.4×	665 1.6×	23 0.2×	48	1.3k

Countries citing papers authored by Courtney E. Bakan

Since Specialization

Citations

This map shows the geographic impact of Courtney E. Bakan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Courtney E. Bakan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Courtney E. Bakan more than expected).

Fields of papers citing papers by Courtney E. Bakan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Courtney E. Bakan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Courtney E. Bakan. The network helps show where Courtney E. Bakan may publish in the future.

Co-authorship network of co-authors of Courtney E. Bakan

This figure shows the co-authorship network connecting the top 25 collaborators of Courtney E. Bakan. A scholar is included among the top collaborators of Courtney E. Bakan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Courtney E. Bakan. Courtney E. Bakan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Efebera, Yvonne A., Ashley Rosko, Craig C. Hofmeister, et al.. (2015). First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 126(23). 1838–1838. 15 indexed citations

Bakan, Courtney E., Craig C. Hofmeister, Yvonne A. Efebera, et al.. (2013). Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunology Immunotherapy. 62(12). 1841–1849. 236 indexed citations

Kolitz, Jonathan E., Stephen L. George, Don M. Benson, et al.. (2013). Recombinant interleukin‐2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. Cancer. 120(7). 1010–1017. 20 indexed citations

Benson, Don M., Craig C. Hofmeister, Swaminathan P. Iyer, et al.. (2012). A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 120(22). 4324–4333. 189 indexed citations

Bakan, Courtney E., Hakju Kwon, Balaji Balasa, et al.. (2011). The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM).. Journal of Clinical Oncology. 29(15_suppl). 2572–2572. 3 indexed citations

Lin, Li, Don M. Benson, Stephanie Deangelis, et al.. (2011). Expression of Concern: A small molecule, LLL12 inhibits constitutive STAT3 and IL‐6‐induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. International Journal of Cancer. 130(6). 1459–1469. 62 indexed citations

Benson, Don M., Courtney E. Bakan, Shuhong Zhang, et al.. (2011). IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 118(24). 6387–6391. 169 indexed citations

Benson, Don M., Courtney E. Bakan, Anjali Mishra, et al.. (2010). The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody. Blood. 116(13). 2286–2294. 660 indexed citations breakdown →

Bill, Matthew A., James R. Fuchs, Chenglong Li, et al.. (2010). The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Molecular Cancer. 9(1). 165–165. 100 indexed citations

10.

Benson, D.M., Swaminathan P. Iyer, Courtney E. Bakan, et al.. (2010). A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma.. Journal of Clinical Oncology. 28(15_suppl). 8139–8139. 2 indexed citations

11.

Benson, Don M., Courtney E. Bakan, Rafat Abonour, et al.. (2010). IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. Blood. 116(21). 1966–1966. 2 indexed citations

12.

Benson, Don M., Mehdi Hamadani, Craig C. Hofmeister, et al.. (2009). Effects of induction with novel agentsversusconventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leukemia & lymphoma. 51(2). 243–251. 11 indexed citations

13.

Benson, Don, Craig C. Hofmeister, Swaminathan P. Iyer, et al.. (2009). Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.. Blood. 114(22). 2880–2880. 1 indexed citations

14.

Benson, Don, Courtney E. Bakan, Shuhong Zhang, et al.. (2009). IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.. Blood. 114(22). 3870–3870. 3 indexed citations

15.

Benson, D.M., François Romagné, Patrick Squiban, et al.. (2009). Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results. Journal of Clinical Oncology. 27(15_suppl). 3032–3032. 3 indexed citations

16.

Bill, Matthew A., Courtney E. Bakan, Don M. Benson, et al.. (2009). Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Molecular Cancer Therapeutics. 8(9). 2726–2735. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact